Sutimlimab (Enjaymo)
Jump to navigation
Jump to search
Mechanism of action
Anti-C1s antibody
Diseases for which it is used
History of changes in FDA indication
- 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
History of changes in EMA indication
- 11/15/2022: Initial authorization
Also known as
- Code name: BIVV009
- Generic name: sutimlimab-jome
- Brand name: Enjaymo